Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences
Sonoma Pharmaceuticals, a leader in hypochlorous acid products for healthcare, has announced CEO Amy Trombly and CFO Jerry Dvonch will present at two virtual conferences: the H.C. Wainwright Global Life Sciences Conference from March 9-10, 2021, and the Maxim Emerging Growth Conference from March 17-18, 2021. Both presentations will be available on demand. Investors interested in meetings with management can contact the respective conference coordinators. Sonoma's products address various health issues and are available in 54 countries.
- None.
- None.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences.
Event |
|
H.C. Wainwright Global Life Sciences Conference |
Date |
|
March 9-10, 2021 |
Presentation |
|
Available on demand beginning March 9, 2021 |
|
|
|
Event |
|
Maxim Emerging Growth Conference |
Date |
|
March 17-18, 2021 |
Presentation |
|
Available on demand beginning March 17, 2021 |
Investors interested in arranging a meeting with the Company’s management for these conferences should contact the respective conference coordinator.
The presentations and panel will be available for registered attendees of each conference to view. Access to the H.C. Wainwright conference presentation will be available HERE. Access to the Maxim conference presentation will be available HERE. In addition, the presentation was furnished on a current report on Form 8-K with the U.S. Securities and Exchange Commission via EDGAR.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin and oxygenates the cells in the area treated assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 54 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Woodstock, Georgia, with manufacturing operations in Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact businessdevelopment@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ is a trademark or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006115/en/
FAQ
What conferences will Sonoma Pharmaceuticals (SNOA) participate in March 2021?
When will the presentations for Sonoma Pharmaceuticals (SNOA) be available?
How can investors arrange meetings with Sonoma Pharmaceuticals (SNOA) management during the conferences?
What products does Sonoma Pharmaceuticals (SNOA) develop?
What are the key benefits of Sonoma Pharmaceuticals' (SNOA) products?
